Medovate signs exclusive agreement with Sela Medical Ltd to distribute SAFIRA™ across Israel

3rd November, 2020

Medical device development company Medovate, is delighted to sign an exclusive agreement with Sela Medical Ltd to distribute SAFIRA™ (SAFer Injection for Regional Anaesthesia) across Israel.

Developed by clinicians for clinicians, the revolutionary Class II medical device is set to transform regional anaesthesia, making it a one-person procedure and putting the control of the injection into the hands of the anaesthetist.

This significant change in procedure will not only help free up resources, it also provides a unique patient safety solution reducing the risk of nerve damage. In addition, the pioneering device has the potential to generate time and cost savings.

After recently receiving European CE mark approval, this distribution agreement with Sela Medical to bring SAFIRA™ to market in Israel marks a significant step for UK based Medovate and is part of the company’s worldwide product roll out.

Founded in 2001, Sela Medical is a well-respected and established distributor within the Israeli market. Their main areas of expertise are Interventional Neuroradiology, General Surgery, Neurosurgery Urology and Aesthetics. Their customers include all the Israeli hospitals, private clinics and the Ministry of Health.

Chris Rogers, Sales and Marketing Director, Medovate, commented:

“We are pleased to have signed an agreement with Sela Medical and are looking forward to working with Ami and the team to distribute SAFIRA™ across the Israeli region. SAFIRA™ was designed in collaboration with anaesthetists in the UK National Health Service (NHS) and we are delighted that such an innovative device will soon be available for clinicians to use across Israel.”

Ami Shalom, VP of Business Development, Sela Medical, added:

“We are delighted to be working with Medovate and to be distributing such an innovative device. Our mission is to deliver premier healthcare products for doctors and patients and we believe SAFIRA™ exceeds this. It will not only improve patient safety and reduce risk in regional anaesthesia techniques, but it will also transform regional anaesthesia procedures going forward. This is an extremely exciting opportunity for us and are looking forward to working closely with the Medovate team.”

Spun out of the NHS in 2017, Medovate works to identify and bring to market high potential innovations, providing vital expertise and funding to support these through clinical trials, regulatory approval and market launch.

Medovate has established itself as a key player in the medtech industry for medical devices relating to its specialisms of anaesthesia, airway management, critical care and surgery.

SAFIRA™ has already been launched across the United States following FDA clearance and now after receiving CE Mark Approval, can be readily integrated into other healthcare markets. Medovate also recently signed a distribution agreement for SAFIRA™ in Australia and New Zealand.

*** *** ***

More about Sela Medical:

More about SAFIRA: Product page: SAFIRA­®